高尔基糖蛋白73在早期原发性肝癌中的表达及意义

doi:10.3877/cma.j.issn.1674-0793.2017.01.003

中华普通外科学文献(电子版) ›› 2017, Vol. 11 ›› Issue (01) : 9 -12. doi: 10.3877/cma.j.issn.1674-0793.2017.01.003

所属专题：文献；

论著

高尔基糖蛋白73在早期原发性肝癌中的表达及意义

张金玲¹, 吴超², 赵志辉³^,^†(

)

^1. 276600　山东省临沂市莒南县人民医院消化内科
^2. 276600　山东省临沂市莒南县人民医院普外科
^3. 430007　武汉，华中科技大学同济医学院附属梨园医院普外科

收稿日期:2016-10-24 出版日期:2017-02-01
通信作者: 赵志辉
基金资助:
湖北省卫生厅科研项目(JX6B54)

Expression and significance of Golgi glycoprotein-73 in early hepatocellular carcinoma

Jinling1 Zhang¹, Chao Wu², Zhihui Zhao³^,^†()

^1. Department of Gastroenterology, People's Hospital of Junan County, Linyi 276600, China
^2. Department of General Surgery, People's Hospital of Junan County, Linyi 276600, China
^3. Department of General Surgery, Liyuan Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430007, China

Received:2016-10-24 Published:2017-02-01
Corresponding author: Zhihui Zhao
About author:
Corresponding author: Zhao Zhihui, Email: 18369500712@qq.com

全文 ( ) 下载PDF ( ) 导出引用

目的

研究高尔基糖蛋白73（GP73）在早期肝癌、慢性乙型肝炎和健康者血液及肝组织中的表达情况，通过比较探讨GP73在早期肝癌中的表达及意义。

方法

采用酶联免疫反应双抗体夹心（ELISA）法检测30例成年健康者（正常组）、30例慢性乙型肝炎患者（肝炎组）及50例早期肝细胞癌（肝癌组）患者血清中GP73的质量浓度，免疫组织化学法检测20例正常肝脏、30例慢性乙型肝炎及30例早期HCC组织中GP73蛋白的表达情况。

结果

(1)肝癌组患者血清中GP73蛋白的质量浓度为（143.01±38.09）μg/L，显著高于正常组的（66.01±25.45）μg/L及肝炎组的（89.78±26.98）μg/L，且GP73蛋白在正常组、肝炎组及肝癌组血清中的质量浓度依次升高（均P<0.01）；(2) GP73蛋白在肝癌组标本中的蛋白表达分别高于肝炎组及正常组，阳性率分别为83.33%、56.67%和15.00% （χ²=5.08、22.74），肝炎组又高于正常组（χ²=8.68），差异均有统计学意义（P<0.05）。

结论

GP73蛋白在早期HCC中呈明显高表达，早期HCC患者血清中GP73蛋白的质量浓度明显高于慢性乙型肝炎及健康者；同时GP73蛋白在慢性乙型肝炎患者血清中的质量浓度亦高于健康者，提示GP73表达的升高可能与慢性HBV感染有关，可能参与了HCC的早期发生、发展。

关键词: 癌，肝细胞, 糖蛋白类, 肝炎，乙型，慢性, 高尔基糖蛋白73, 免疫组织化学

Objective

To compare the expression of Golgi glycoprotein-73 (GP73) in blood serum and tissues of early hepatocellular carcinoma (HCC), chronic hepatitis B (HBV) and healthy adults, and discuss the significance of GP73 in early HCC.

Methods

Enzyme-linked immunosorbent assay (ELISA) method was used to detect the concentration of GP73 in serum of 30 healthy adults (normal group), 30 cases with HBV (hepatitis group) and 50 cases with early HCC (cancer group). Immunohistochemical method was used to detect the tissue expression of GP73 in 20 cases of normal liver, 30 cases with chronic HBV and 30 cases with early HCC.

Results

(1) The serum concentration of GP73 in patients with early HCC was (143.01±38.09) μg/L, significantly higher than normal group (66.01±25.45) μg/L and hepatitis group (89.78±26.98) μg/L. And the concentration of GP73 increased gradually in normal, hepatitis and cancer groups (all P<0.01). (2) The expression of GP73 in early HCC tissues was higher than that in hepatitis and normal groups, the positive rates were 83.33%, 56.67% and 15.00%, respectively ( χ²=5.08, 22.74). And the positive rate of hepatitis group was higher than normal group, the difference was statistically significant ( χ²=8.68, P<0.05).

Conclusions

GP73 shows high expression in the early HCC, and GP73 in serum of HCC is significantly higher than that of chronic HBV patients and healthy adults. Meanwhile, the concentration of GP73 in serum of patients with chronic HBV is higher than that of healthy adults, suggesting that the increased expression of GP73 may be related with chronic HBV infection, and the early occurrence and development of HCC may be involved in GP73.

Key words: Carcinoma, hepatocellular, Glycoproteins, Hepatitis B, Chronic, Golgi glycoprotein-73, Immunohistochemistry

图1 GP73在各组织标本中的免疫组织化学染色结果（×200）　A为GP73在早期肝癌组织中的阳性表达；B为肝癌中阴性表达；C为肝炎组织中GP73阳性表达；D为肝炎中阴性表达；E为正常肝脏组织中GP73阳性表达；F为正常肝脏组织中阴性表达

图2 GP73蛋白在正常组、肝炎组及肝癌组血清中的表达，质量浓度依次升高

表1 GP73在血清各组中的表达

组别	n	质量浓度（μg/L，±s）^a	阳性表达率[n(%)]^b
正常组	30	66.01±25.45	4（13.33）
肝炎组	30	89.78±26.98	14（46.67）
肝癌组	50	143.01±38.09	48（96.00）
统计值		3.510, 9.822, 6.704^a	7.937, 46.322, 26.170^b
P₁, ₂, ₃值		<0.01, <0.01, <0.01	0.005, <0.01, <0.01

表1 GP73在血清各组中的表达

组别	n	质量浓度（μg/L，±s）^a	阳性表达率[n(%)]^b
正常组	30	66.01±25.45	4（13.33）
肝炎组	30	89.78±26.98	14（46.67）
肝癌组	50	143.01±38.09	48（96.00）
统计值		3.510, 9.822, 6.704^a	7.937, 46.322, 26.170^b
P₁, ₂, ₃值		<0.01, <0.01, <0.01	0.005, <0.01, <0.01

[1]	Kladney RD,Bulla GA,Guo L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene, 2000, 249(1-2): 53-65.
[2]	张启暝,何东风,李洪义. 高尔基蛋白73在原发性肝癌诊治中的意义[J]. 现代肿瘤医学, 2015, 23(17): 2452-2455.
[3]	中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肿瘤学杂志, 2011, 16(10): 929-946.
[4]	Pang RW,Joh JW,Johnson PJ, et al. Biology of hepatocellular carcinoma[J]. Ann Surg Oncol, 2008, 15(4): 962-971.
[5]	BERGSTRAND CG,CZAR B. Paper electrophoretic study of human fetal serum proteins with demonstration of a new protein fraction[J]. Scand J Clin Lab Invest, 1957, 9(3): 277-286.
[6]	Abelev GI. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data[J]. Cancer Res, 1968, 28(7): 1344-1350.
[7]	Shan SG,Gao YT,Xu YJ, et al. Gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients[J]. Hepatol Res, 2013, 43(11): 1199-1210.
[8]	蔡云峰,甄作均,陈焕伟, 等. 肝癌术后肝再生状态与肝癌复发关系的初步研究[J]. 中国普通外科杂志, 2008, 17(7): 692-696.
[9]	Benzoni E,Lorenzin D,Favero A, et al. Liver resection for hepatocellular carcinoma: a multivariate analysis of factors associated with improved prognosis. The role of clinical, pathological and surgical related factors[J]. Tumori, 2007, 93(3): 264-268.
[10]	Stefaniuk P,Cianciara J,Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2010,16(4): 418-424.
[11]	Gambarin-Gelwan M,Wolf DC,Shapiro R, et al. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation[J]. Am J Gastroenterol, 2000, 95(6): 1535-1538.
[12]	Block TM,Comunale MA,Lowman M, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans[J]. Proc Natl Acad Sci U S A, 2005, 102(3): 779-784.
[13]	Mao Y,Yang H,Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12): 1687-1693.
[14]	Yamamoto K,Imamura H,Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J]. J Gastroenterol, 2010, 45(12): 1272-1282.

[1]	中国医师协会肝癌专业委员会. 肝细胞癌伴微血管侵犯诊断和治疗中国专家共识（2024版）[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 313-324.
[2]	汤宏涛, 何坤. 中晚期肝细胞癌介入治疗的进展及前景[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 305-308.
[3]	李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4]	常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[5]	屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6]	公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[7]	李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[8]	刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[9]	焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[10]	陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[11]	袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[12]	吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[13]	邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[14]	王向前, 李清峰, 陈磊, 丘文丹, 姚志成, 李熠, 吴荣焕. 姜黄素抑制肝细胞癌索拉非尼耐药作用及其调控机制[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 729-735.
[15]	谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Expression and significance of Golgi glycoprotein-73 in early hepatocellular carcinoma

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Expression and significance of Golgi glycoprotein-73 in early hepatocellular carcinoma